Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hyperinsulinemic-euglycemic clamp Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1

NCT00574665
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hyperglycemic Clamp
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 21, 2026, 10:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Insulin and Muscle Fat Metabolism

NCT04759872
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Sedentary Lifestyle
Interventions
Hyperinsulinemic-euglycemic Clamp
Other
Lead sponsor
Oregon State University
Other
Eligibility
30 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 21, 2026, 10:39 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance

NCT07516509
View directory record Official record
Conditions
Insulin Resistance
Interventions
VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response of Epinephrine

NCT02692313
View directory record Official record
Conditions
Diabetes Complications
Interventions
Epinephrine, Saline infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Early Phase 1 Interventional Results available

Adrenergic System in Islet Transplantation

NCT03079921
View directory record Official record
Conditions
Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions
Phentolamine, Propranolol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin

NCT00843791
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
placebo, pioglitazone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fat Induced Insulin Resistance and Atherosclerosis

NCT02348190
View directory record Official record
Conditions
Other Fatty Acid Oxidation Disorders, Diabetes Mellitus, Insulin Resistance
Interventions
Lipid/heparin
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 21, 2026, 10:39 AM EDT
Not listed Not applicable Interventional

Impact of Acute Exercise on Vascular Insulin Sensitivity in Metabolic Syndrome

NCT03894527
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Single Bout of Exercise, Control Condition
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 21, 2026, 10:39 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Not applicable Interventional

Effect of Pulsatile Hormone Administration on Insulin Action

NCT06216665
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Continuous Insulin administration during hyperinsulinemic euglycemic clamp test, Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 21, 2026, 10:39 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092
View directory record Official record
Conditions
Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions
Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed No phase listed Observational

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

NCT03195400
View directory record Official record
Conditions
IGT - Impaired Glucose Tolerance, T2D
Interventions
Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 21, 2026, 10:39 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
View directory record Official record
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Phase 1 Interventional

The Role of Endocannabinoids in Insulin Production and Action

NCT01517100
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nabilone, CP-945,598, hyperglycemic clamp, euglycemic-hyperinsulinemic clamp
Other · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes

NCT03582956
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Adiposity
Interventions
Euglycemic hyperinsulinemic clamp with tracer enhancement
Procedure
Lead sponsor
Yale University
Other
Eligibility
12 Years to 24 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 21, 2026, 10:39 AM EDT
Recruiting Not applicable Interventional

Mechanisms of Ultrasound Neuromodulation Effects in Diabetes

NCT06042517
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp
Device · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 10:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fatty Acid Oxidation Defects and Insulin Sensitivity

NCT02517307
View directory record Official record
Conditions
Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions
Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 10:39 AM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 21, 2026, 10:39 AM EDT